Scary really! How about the insiders' buying and large positions taken by Fidelity as well as other big funds? I would follow those who know the co with resources to do DD before their purchase. Those insider purchases were all at higher prices. They put money where their mouths are. This co is fine just based on such observations. Of course if you are not an investor, but a short term trader, that's another story.
Halozyme Therapeutics Issues Financial Guidance For 2013
SAN DIEGO, Jan. 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, today announced that the Company ended 2012 with a cash balance of approximately $100 million and expects 2013 net cash burn to be between $45 and $50 million. The Company also announced it secured a $30 million term loan from Oxford Finance and Silicon Valley Bank.
so let's see- 100M balance with money coming in from Pfizer and Roche- bridge loan of 30M to avoid dilution- a stockholder friendly strategy if you ask me- most biotechs couldn't care less and just set up an ATM or secondary- thanks Greg.